Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7387)
All Articles published online
|
Publishing Process of This Article
|
Aug 6, 2017 (publication date) through Feb 1, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kothari MM, Nguyen DL, Parekh NK. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature. World J Gastrointest Pharmacol Ther 2017; 8(3): 155-161 [PMID: 28828193 DOI: 10.4292/wjgpt.v8.i3.155] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v8/i3/155.htm |
| Number | Citing Articles |
| 1 |
Remo Panaccione, Wan-Ju Lee, Ryan Clark, Kristina Kligys, Rhiannon I. Campden, Stacy Grieve, Tim Raine. Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review. Advances in Therapy 2023; 40(5): 2051 doi: 10.1007/s12325-023-02457-6
|
| 2 |
Albert John Bromeo, Irmak Karaca, Hashem H. Ghoraba, Xun Lyu, Ngoc Trong Tuong Than, Prapatsorn Ongpalakorn, Yong Un Shin, Gunay Uludag, Anh Ngoc Tram Tran, Zheng Xian Thng, Diana V. Do, Chi Mong Christopher Or, Quan Dong Nguyen. Risk factors for development of anti-adalimumab antibodies in non-infectious uveitis. Heliyon 2024; 10(9): e29313 doi: 10.1016/j.heliyon.2024.e29313
|
| 3 |
K. Matthew McKay, Nicholas Apostolopoulos, Brian Chou, Thellea K. Leveque, Russell N. Van Gelder. Anti-adalimumab Antibodies in Patients with Non-infectious Ocular Inflammatory Disease: A Case Series. Ocular Immunology and Inflammation 2022; 30(7-8): 1721 doi: 10.1080/09273948.2021.1936565
|
| 4 |
Xiong Chen, Rui Liu, Xiaoming Liu, Canxia Xu, Xiaoyan Wang. Protective Role of Coxsackie-Adenovirus Receptor in the Pathogenesis of Inflammatory Bowel Diseases. BioMed Research International 2018; 2018: 1 doi: 10.1155/2018/7207268
|
| 5 |
Emily M. King, Ronit Mazor, Nicolas Çuburu, Ira Pastan. Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin. The Journal of Immunology 2018; 200(6): 2038 doi: 10.4049/jimmunol.1701430
|
| 6 |
Robert Battat, Dana Lukin, Ellen J Scherl, Suresh Pola, Anand Kumar, Lauren Okada, Lei Yang, Anjali Jain, Corey A Siegel. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2021; 27(9): 1443 doi: 10.1093/ibd/izaa313
|
| 7 |
Cong Dai, Yi-nuo Wang, Wen-ning Tian, Yu-Hong Huang, Min Jiang. The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A systematic review and meta-analysis. International Immunopharmacology 2022; 112: 109269 doi: 10.1016/j.intimp.2022.109269
|
| 8 |
Kristin H. Bjørlykke, Jørgen Jahnsen, Jørn Brynskov, Pauliina Molander, Michael Eberhardson, Loà G. Davidsdottir, Taina Sipponen, Henrik Hjortswang, Guro Løvik Goll, Silje Watterdal Syversen, Ebbe Langholz, Kristin K. Jørgensen, Casper Steenholdt. Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia. Scandinavian Journal of Gastroenterology 2023; 58(1): 25 doi: 10.1080/00365521.2022.2108684
|
| 9 |
Ji Li, Zhanju Liu, Pinjin Hu, Zhonghui Wen, Qian Cao, Xiaoping Zou, Yan Chen, Yingde Wang, Jie Zhong, Xizhong Shen, Dirk Demuth, Olga Fadeeva, Li Xie, Jun Chen, Jiaming Qian. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study. BMC Gastroenterology 2022; 22(1) doi: 10.1186/s12876-021-02074-z
|
| 10 |
Isaiah P. Schuster, Leslie Klyachman, Ramona Rajapakse, Farah Monzur. Inflammatory Bowel Disease. Clinical Gastroenterology 2021; : 89 doi: 10.1007/978-3-030-81780-0_4
|
| 11 |
Tsvetelina Velikova, Metodija Sekulovski, Monika Peshevska-Sekulovska. Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development. Antibodies 2024; 13(1): 16 doi: 10.3390/antib13010016
|
| 12 |
Kyle Gress, Julie A. Bass, Ryan S. Funk, Ryan P. Morrow, Rachel Hasenkamp, Valentina Shakhnovich. Facing Real-World Challenges of Immunogenicity in Pediatric Inflammatory Bowel Disease. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.01148
|
| 13 |
Kazuto Nakae, Sho Masui, Atsushi Yonezawa, Motomu Hashimoto, Ryu Watanabe, Koichi Murata, Kosaku Murakami, Masao Tanaka, Hiromu Ito, Kotoko Yokoyama, Noriko Iwamoto, Takashi Shimada, Miyuki Nakamura, Masaya Denda, Kotaro Itohara, Shunsaku Nakagawa, Yasuaki Ikemi, Satoshi Imai, Takayuki Nakagawa, Makoto Hayakari, Kazuo Matsubara, Masataka Kuwana. Potential application of measuring serum infliximab levels in rheumatoid arthritis management: A retrospective study based on KURAMA cohort data. PLOS ONE 2021; 16(10): e0258601 doi: 10.1371/journal.pone.0258601
|
| 14 |
Iolanda Valentina Popa, Alexandru Burlacu, Catalina Mihai, Cristina Cijevschi Prelipcean. A Machine Learning Model Accurately Predicts Ulcerative Colitis Activity at One Year in Patients Treated with Anti-Tumour Necrosis Factor α Agents. Medicina 2020; 56(11): 628 doi: 10.3390/medicina56110628
|
| 15 |
Tea Lamberg, Taina Sipponen, Sanna Valtanen, Kari K Eklund, Tarja Mälkönen, Kristiina Aalto, Katriina Mikola, Kaija-Leena Kolho, Sanna Leinonen, Pia Isomäki, Heidi Mäkinen, Krista-Liisa Vidqvist, Arto Kokko, Laura Huilaja, Minna Kyllönen, Paula Keskitalo, Sirja Sard, Paula Vähäsalo, Ritva Koskela, Liisa Kröger, Perttu Lahtinen, Anna-Maija Haapala, Katja Korkatti, Tuulikki Sokka-Isler, T. Sakari Jokiranta. Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases. Autoimmunity 2022; 55(5): 275 doi: 10.1080/08916934.2022.2067985
|
| 16 |
Sherman Picardo, Kenji So, Kannan Venugopal. Anti‐TNF‐induced lupus in patients with inflammatory bowel disease. JGH Open 2020; 4(3): 507 doi: 10.1002/jgh3.12291
|
| 17 |
Gjorgi Deriban, Dafina Nikolova, Fani Licoska, Emilija Trpcevska Nikolovska, Vladimir Andreevski, Kalina Stardelova, Vladimir Serafimoski. Biologic Therapy in Inflammatory Bowel Disease - Results from a Single Tertiary Care Center in North Macedonia. PRILOZI 2023; 44(2): 41 doi: 10.2478/prilozi-2023-0023
|
| 18 |
Jeffrey A. Lowell, Garvita Sharma, Vincent Chua, Shomron Ben-Horin, Arun Swaminath, Keith Sultan. Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis. Digestive Diseases and Sciences 2024; 69(10): 3920 doi: 10.1007/s10620-024-08515-5
|
| 19 |
Andrzej M. Kierzek, Timothy P. Hickling, Isabel Figueroa, J. Cory Kalvass, Marjoleen Nijsen, Krithika Mohan, Geertruida M. Veldman, Akihiro Yamada, Hiroyuki Sayama, Sachiko Yokoo, Abhishek Gulati, Renu S. Dhanikula, Jochem Gokemeijer, Tarek A. Leil, Craig J. Thalhauser, Mario Giorgi, Maciej J. Swat, Vijayalakshmi Chelliah, Ben G. Small, Neil Benson, Michael Walker, Kapil Gadkar, Valerie Quarmby, Rong Deng, Andrea Ferrante, Gemma L. Dickinson, Jan‐Stefan Van Der Walt, Lian Zhou, Xiaoying Chen, Hannah M. Jones, Jatin Narula, Sophie Tourdot, Thierry Lavé, Benjamin Ribba, Piet H. van der Graaf. A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins. CPT: Pharmacometrics & Systems Pharmacology 2019; 8(11): 773 doi: 10.1002/psp4.12465
|
| 20 |
Naamah Zitomersky, Lisa Chi, Enju Liu, Kurtis R. Bray, Konstantinos Papamichael, Adam S. Cheifetz, Scott B. Snapper, Athos Bousvaros, Jocelyn A. Silvester. Anti‐infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition 2024; 78(2): 261 doi: 10.1002/jpn3.12074
|